Recovery

Research only

These are not on an FDA list that allows compounding, or we have not yet read their status. We cover the research on them and link no seller.

• BPC-157

  Research only

  On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.

  Source:FDA document, read September 2026.Also:PharmExec (vote counts)NCPA (outcome)

  36 sellers we track list it; none publishes a price yet.

• CJC-1295

  Research only

  On no FDA compounding list. The name does not appear in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025), so neither a 503A pharmacy nor a 503B outsourcing facility has a listed route to it.

  Source:FDA document, read September 2026.Also:FDA 503B bulk drug substances categories (updated March 21, 2025)

  19 sellers we track list it; none publishes a price yet.

• Ipamorelin

  Research only

  "Ipamorelin Acetate" is in 503B Category 2, bulk drug substances that raise significant safety risks (list updated March 21, 2025). It is named on no 503A list, so neither an outsourcing facility nor a 503A pharmacy has a listed route to it.

  Source:FDA document, read September 2026.Also:FDA 503A bulk drug substances categories (updated May 14, 2026)

  22 sellers we track list it; none publishes a price yet.

• TB-500

  Research only

  On no FDA compounding list: absent from the 503A categories (updated May 14, 2026) and the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.

  Source:FDA document, read September 2026.Also:PharmExec (vote counts)NCPA (outcome)FDA 503B bulk drug substances categories (updated March 21, 2025)

  24 sellers we track list it; none publishes a price yet.

• MK-677

  Research only

  "Ibutamoren Mesylate" is in 503A Category 2, bulk drug substances that raise significant safety risks (list updated May 14, 2026), and in 503B Category 2 (updated March 21, 2025). Both lists bar it for the same stated reason.

  Source:FDA document, read September 2026.Also:FDA 503B bulk drug substances categories (updated March 21, 2025)

  3 sellers we track list it; none publishes a price yet.

• Thymosin alpha-1

  Research only

  "Thymosin alpha-1" is in 503B Category 3, bulk drug substances nominated without adequate support (list updated March 21, 2025). It is named on no 503A list, so no listed compounding route exists for it.

  Source:FDA document, read September 2026.Also:FDA 503A bulk drug substances categories (updated May 14, 2026)

  7 sellers we track list it; none publishes a price yet.

• KPV

  Research only

  On no FDA compounding list. KPV appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.

  Source:FDA document, read September 2026.Also:PharmExec (vote counts)NCPA (outcome)FDA 503B bulk drug substances categories (updated March 21, 2025)

  17 sellers we track list it; none publishes a price yet.

• LL-37

  Research only

  On no FDA compounding list. Neither LL-37 nor cathelicidin, the family it belongs to, appears in the 503A bulk drug substances categories (updated May 14, 2026) or the 503B categories (updated March 21, 2025).

  Source:FDA document, read September 2026.Also:FDA 503B bulk drug substances categories (updated March 21, 2025)

  3 sellers we track list it; none publishes a price yet.

Research on recovery

1. GHK-Cu Copper Toxicity: Copper per Milligram vs the Upper LimitGHK-Cu is 7% to 16% copper by weight, depending on the form. Here is that figure beside the 10,000-microgram adult upper limit, and why the limit was set for copper you eat.
2. LL-37 peptide: real trials, for something elseLL-37 has randomized controlled trials behind it, which is rare here. They tested a cream on leg ulcers, and the 148-patient phase IIb found no improvement across the full population.
3. KPV peptide: what the research actually showsKPV is the three-amino-acid tail of alpha-MSH. Its anti-inflammatory effect is repeatable in cell lines and mouse colitis, and it has never been tested in a person.
4. BPC 157 Before and After: What the Human Reports MeasuredThe published human record is three uncontrolled reports from one clinic. The most quoted result, 11 of 12 knees improved, came from a phone survey whose own authors state that no tool measured function or stiffness.
5. TB 500 Dosage: What Human Studies of Thymosin Beta-4 UsedNo published human study has given TB-500 itself. The doses that exist belong to full-length thymosin beta-4: four ascending intravenous cohorts of healthy volunteers, a 0.1% eye drop, and a microgram-per-kilogram schedule in rats.
6. MK-677 Side Effects: What the Ibutamoren Trials RecordedA trial in 123 hip-fracture patients was stopped early for a congestive heart failure signal, and FDA cites it by name. A two-year trial in 65 healthy older adults found increased appetite, ankle swelling and rising fasting glucose.
7. Thymosin Alpha 1: What the Human Trials Actually MeasuredA peptide with three decades of trials behind it. The largest sepsis trial, 1,106 adults, found 23.4% mortality against 24.1% on placebo, and a 2026 Cochrane review of the hepatitis B trials rated almost every outcome very low certainty.
8. GHK-Cu Benefits: Which Claims Have Been Tested in PeopleThe copper peptide is credited with firmer skin, faster healing, thicker hair and less inflammation. Most of that list comes from cells and animals; the human trials are few and applied to the skin.
9. Peptides for Inflammation: Which Ones Have Human EvidenceOf the four peptides here, only semaglutide has a large randomized trial showing an inflammation marker fall. GHK-Cu and BPC-157 rest on cell and animal work, and glutathione's one trial was not significant.
10. GHK-Cu Dosage: What Studies Applied, and Why No Injected Dose ExistsNo label sets a GHK-Cu dose. The only strength tested against placebo, a 0.4% cream on leg ulcers, did no better than placebo, and no study has tested it by injection in people.
11. BPC 157 and TB 500 Together: What Any Study Has Tested of the PairOne rat study tested the pair against each alone, and the combination added nothing. In people, the record is 4 survey patients and one FDA adverse-event report.
12. BPC 157 Dosage: Why No Human Dose Exists, and What Studies UsedNo trial has set a human dose of BPC-157. Here is what the rat studies and three small human reports gave, and why none of it translates into a dose for a person.
13. BPC-157: What Human Evidence Actually ExistsThirty-five animal and cell studies, and three small human reports with no control group. What each one measured, and what it did not.
14. BPC-157 Side Effects: What Has Been Recorded in PeopleThree tiny uncontrolled reports found no adverse events. That is weaker than it sounds, and the FDA says it lacks the data to judge harm.
15. GHK-Cu Side Effects: What Topical Studies Report, and the Injected UnknownsOnly two small trials have tested GHK-Cu alone on skin, and copper is a weak allergen. Injected GHK-Cu has no human safety record, and the FDA flags its risks.
16. GHK-Cu: Copper Peptide Evidence, Topical Versus InjectedTwo small skin trials, no injection trials, and an FDA list that allows the peptide by every route except the needle. What each route has behind it.
17. Peptides for Hair Growth: What the Trials ShowThe peptides sold for hair have small trials, all of blends. The best one found is 32 people using a peptide blend that matched 3% minoxidil.
18. Peptides for Joint Pain: What Human Trials Exist, Compound by CompoundOral collagen peptides have randomized trials, with modest benefits and a high risk of bias. BPC-157 has one uncontrolled chart review, and TB-500 has none.
19. Peptides for Muscle Growth: What Trials of GH Secretagogues MeasuredDrugs that raise growth hormone added about a kilogram of lean mass in randomized trials. Strength mostly stayed the same, and blood sugar went up.
20. Peptides for Skin: Which Ones Have Human TrialsCream peptides, copper peptide and swallowed collagen are three different things. One has a 93-person split-face trial, one has two small trials, and one has 26.
21. TB-500: What Is Known, and What Has Never Been TestedA seven-amino-acid fragment with no human data, borrowing its reputation from small trials of the full protein. What each study actually used.